MoneyWorks4Me

Cadila Healthcare informs about press release

06 Sep 2021 Evaluate

Cadila Healthcare has informed that it enclosed a copy of press release dated September 6, 2021 titled ‘Zydus Cadila’s Sitagliptin base tablets receives Tentative Approval from FDA’.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

1116.50 11.50 (1.04%)
20-Aug-2026 12:39 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1898.20
Dr. Reddys Labs. 1179.50
Cipla 1433.95
Lupin 2220.85
Zydus Lifesciences 1116.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: